Oct 30, 2026 · 1h 1m
Biotech weighs AI promise against biology’s stubborn bottlenecks
Episode 201 - October 30, 2026
The panel connects biotech’s market reset, AI ambitions, clinical failures, and oncology advances to the sector’s central question: where can innovation actually improve outcomes?
- 1Pharma still seeks early and clinical-stage deals, while rates and geopolitical risks keep biotech markets fragile.
- 2AI may improve discovery, data analysis, and patient selection, but human biology and clinical development remain difficult bottlenecks.
- 3Strong oncology survival data contrasts with Alzheimer’s failure, underscoring biotech’s uneven path from scientific promise to investment returns.
Don't miss
The panel highlights unusually strong overall-survival results from Amgen’s Delphi 305 trial and considers whether they could change small-cell lung cancer care.
The brief
Sam Fazeli, Chris Garabedian, Brian Skorney, and Jeroen Werber survey a biotech sector balancing renewed dealmaking and IPO activity against rates, geopolitics, and uneven public-market performance.
Anthropic’s life-sciences expansion sharpens the AI debate: molecule generation and data analysis may improve, but target biology, clinical development, and human oversight remain unresolved.
Alnylam’s earnings raise a strategic question about using strong stock currency to diversify, while Acumen’s failed Alzheimer’s trial shows how quickly binary risk can erase value.
Rare-disease policy, Palvella, and Kidney Week point to renewed development activity, including improving outcomes and more partnerships between U.S. and Chinese biotech companies.
At ESMO, Amgen’s Delphi 305 survival results stand out as a potential standard-of-care shift, alongside debate over BioNTech, Moderna, and next-generation vaccine platforms.
What was said on this episode
32 statements · 20 positive · 8 negative · 3 mixed · 1 neutral
The biotech M&A market may improve relative to the third quarter.
“we should see a better M&A market than the third quarter”
Listen at 2:50
AI will substantially drive efficiency in biotech.
“AI is going to be a big, big factor kind of driving efficiencies.”
Listen at 9:07
AI-generated assets will increase, but trial capacity will remain limited.
“we're going to have a lot more um you know uh you know pucks to shoot the goal but you still have a limitation of how many trials you can do”
Listen at 11:00
AI will support the biotech industry’s shift toward smaller teams.
“this idea of smaller teams is here to stay, and AI is going to facilitate that.”
Listen at 13:53
AI can replace two or three contractors for some data-gathering tasks.
“i can displace two or three contractors, for instance, in some data gathering”
Listen at 14:48
Human review remains necessary to finalize AI-gathered data quality.
“I still need the human in the loop to finalize the quality of the data”
Listen at 14:56
Clinical development, not target identification or design, is drug development’s main bottleneck.
“the real bottleneck in drug development isn't sort of, target identification, you know, drug design, the bottleneck is clinical development.”
Listen at 17:51
AI efficiencies will be meaningful but will not accelerate drug development by 90%.
“I think the efficiencies that it will bring. be meaningful, but more marginal and certainly not accelerate things by 90%.”
Listen at 18:23
AI will be transformational, especially for biotech.
“AI will be transformational for everyone, but particularly in biotech.”
Listen at 18:36
AI is unlikely to change the duration of clinical outcome studies.
“I don't see how that. is going to be changed by ai”
Listen at 19:26
Amgen enrolled its Lp(a) study in 16 months, faster than Novartis.
“they are leap and bounce faster than anybody else recall they enrolled their lp little a study in 16 months”
Listen at 20:39
AI and informatics enable faster clinical-trial enrollment.
“they're able to enroll super quickly so we're already seeing some of these benefits”
Listen at 21:01
Biotech IPO issuance reached approximately 31 year to date.
“year-to-date count, at least by my unofficial. uh count i think we're at 31”
Listen at 24:19
Lycia Therapeutics shares rose about 60% on their first trading day.
“The stock actually popped about 60% last week on its first day of trading”
Listen at 24:52
At least half of recent biotech IPO stocks trade below debut prices.
“at least half are down versus their debut price”
Listen at 26:36
“This could be a record setting year for FDA approved drugs”
Listen at 27:34
A major Iran-related attack could raise oil prices and interest rates.
“a massive jump in oil prices could result in higher interest rates”
Listen at 28:14
Higher interest rates negatively affect biotech markets.
“interest rates, which we would love to believe that are not related, are not impacting biotech. But I think they do if they go high enough.”
Listen at 28:41
Palvella’s Qtorin rapamycin product is expected to receive approval.
“there's going to be an approval here.”
Listen at 35:16
Acumen’s Phase 2 Alzheimer’s candidate failed, sending shares down 80%.
“it failed. The data were announced today. It's a phase two trial. The stock is down 80%.”
Listen at 36:01
Atsuka’s sibeprenlimab stopped IgA-nephropathy progression in the study.
“this drug stopped disease progression”
Listen at 39:39
Sibeprenlimab produced one kidney event versus 28 with placebo.
“one kidney event on treatment versus 28. on placebo.”
Listen at 40:03
Amgen’s Delphi 305 data appeared practice-changing in small-cell lung cancer.
“I did see at least that as a practice-changing data set.”
Listen at 43:21
Delphi 305 is likely to change small-cell lung-cancer standard of care.
“this is standard of care changing.”
Listen at 49:45
Delphi 312 is expected to succeed after Delphi 305.
“I'm pretty convinced will be successful too”
Listen at 50:01
Ivanezumab improved overall and progression-free survival versus control.
“This hit both on overall survival and on progression-free survival.”
Listen at 52:30
The discussed oncology drugs are active but likely provide modest benefits.
“these are active drugs they're probably providing a modest benefit”
Listen at 53:13
Genmab’s frontline Abkiney data showed a 51% reduction in death and progression.
“a 51% reduction in death and progression.”
Listen at 54:16
Genmab’s ovarian-cancer trial showed a 60–70% reduction in death.
“with a 60% to 70% reduction in death.”
Listen at 54:42
Genmab’s strong oncology data may justify a higher stock valuation.
“this is a stock that you could see is now getting remunerated”
Listen at 56:48
B1 is a major competitor in the PRMT5 oncology market.
“B1 is a huge competitor.”
Listen at 1:00:03
B1 currently has one of oncology’s strongest pipelines.
“the B1 pipeline is one of the best in the industry right now in oncology.”
Listen at 1:00:12
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Books & mentions
Some links are affiliate links — PodLume may earn a commission if you buy.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.